Stewart Frank, MD
Cardiovascular Disease · San Diego, CANPI 1417051558
Payments from drug & device makers
Across 157 payments — averaging $22.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$536
- Novartis$394
- AstraZeneca$340
- Novo Nordisk$279
- Johnson & Johnson$226
- Lilly USA, LLC$203
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,44099%
- Education$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 26 | $536 |
| Novartis | 17 | $394 |
| AstraZeneca | 17 | $340 |
| Novo Nordisk | 16 | $279 |
| Johnson & Johnson | 8 | $226 |
| Lilly USA, LLC | 8 | $203 |
| Gilead | 7 | $180 |
| Pfizer | 8 | $179 |
| GSK | 9 | $155 |
| Exact Sciences | 7 | $150 |
| Seqirus USA Inc | 4 | $93 |
| Amgen | 4 | $72 |
| Intuitive Surgical | 1 | $60 |
| Boston Scientific | 1 | $60 |
| Boehringer Ingelheim | 2 | $49 |
| Currax Pharmaceuticals LLC | 2 | $39 |
| Viiv Healthcare Company | 1 | $36 |
| Phadia US Inc. | 2 | $34 |
| Lundbeck LLC | 1 | $33 |
| Philips North America LLC | 1 | $32 |
| Azurity Pharmaceuticals, Inc. | 2 | $30 |
| Si-bone, Inc. | 1 | $28 |
| Hologic Sales And Service, LLC | 1 | $28 |
| Aimmune Therapeutics, Inc. | 1 | $27 |
| Halozyme Inc | 1 | $26 |
| Merck | 1 | $24 |
| Abiomed | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Bayer | 1 | $19 |
| Verity Pharmaceuticals Inc. | 1 | $18 |
| Itamar Medical Inc | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Antares Pharma, Inc. | 1 | $16 |
How this compares
$3,465 in reported general payments places this provider in the 55th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 127 | $128,548 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $47,006 |
| JanuviaSitagliptin Phosphate | 21 | $32,645 |
| JardianceEmpagliflozin | 23 | $21,531 |
| TrulicityDulaglutide | 13 | $18,279 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $12,990 |
| MyrbetriqMirabegron | 12 | $8,063 |
| Losartan Potassium | 504 | $5,737 |
| Levothyroxine Sodium | 362 | $4,855 |
| Rosuvastatin Calcium | 297 | $4,377 |
| Atorvastatin Calcium | 317 | $2,952 |
| Ezetimibe | 71 | $2,040 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 114 | $2,027 |
| Carvedilol | 213 | $1,951 |
| Omeprazole | 171 | $1,850 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $179 | $128,548127 claims |
| GileadGenvoya | $180 | $47,00612 claims |
| MerckJanuvia | $24 | $32,64521 claims |
| Boehringer IngelheimJardiance | $49 | $21,53123 claims |
| Lilly USA, LLCTrulicity | $203 | $18,27913 claims |
| GSKTrelegy Ellipta | $155 | $12,99017 claims |
| AbbVieSynthroid | $536 | $95625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in San Diego
- Lori DanielsSan Diego$10.2M
- Michael WilkinsonSan Diego$1.9M
- William PennySan Diego$829K
- Ajit RaisinghaniSan Diego$695K
- Kevin KingSan Diego$598K
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.